How is the dose of Platinib determined?

Pralsetinib (Pralsetinib) is a kinase inhibitor mainly used to treat metastatic RET fusion-positive non-small cell lung cancer (NSCLC) and thyroid cancer. When patients determine the dosage of platinib, doctors will consider multiple factors of the patient, including weight, body surface area, age, gender, overall health, comorbidities, and drug interactions. For elderly patients, because their liver and kidney functions may be relatively weak, doctors may adjust the dose according to the situation. Prior to the use of platinib, the presence of RET gene fusions in patients' thyroid cancer or non-small cell lung cancer must be determined. This is critical to ensure patients benefit from treatment and avoid unnecessary drug use.